Mathematical model of HPV provides insight into impacts of risk factors and vaccine

PLoS Medicine

Volumn 3, Issue 5, 2006, Pages 587-588

  Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

HUMAN; MATHEMATICAL MODEL; MEDICAL RESEARCH; RISK FACTOR; SEROPREVALENCE; SHORT SURVEY; VACCINATION; VIRUS INFECTION; WART VIRUS; COST OF ILLNESS; DEVELOPING COUNTRY; ECONOMICS; FEMALE; FINLAND; FORECASTING; IMMUNOLOGY; NOTE; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; THEORETICAL MODEL; UTERINE CERVIX TUMOR; VIROLOGY;

COST OF ILLNESS; DEVELOPING COUNTRIES; FEMALE; FINLAND; FORECASTING; HUMANS; MODELS, THEORETICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 33744476125     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030164     Document Type: Short Survey

References (12)

1. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 88: 63-73.
2. Clifford GM, Smith JS, Aguado T, Franceschi S (2003) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 89: 101-105.
3. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, et al. (2003) A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106: 896-904.
4. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, et al. (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96: 604-615.
5. Garnett GP, Waddell HC (2000) Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 19: 101-111.
6. Hughes JP, Garnett GP, Koutsky L (2002) The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13: 631-639.
7. Sanders GD, Taira AV (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9: 37-48.
8. Taira AV, Neukermans CP, Sanders GD (2004) Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10: 1915-1923.
9. Kulasingam SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290: 781-789.
10. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, et al. (2006) Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses. PLoS Med 3: e138. DOI: 10.1371/journal.pmed.0030138
11. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151: 1158-1171.
12. Syrjanen KJ, Syrjänen S (2000) Papillomavirus infections in human pathology. Chichester (United Kingdom): Wiley. 630 p.